Ownership of Joint Technology. Subject to Section 6.2 and the license grants under Article 2, the Parties shall each own an equal, undivided interest in and to any and all (a) Information and Inventions, conceived, discovered, developed or otherwise made, jointly by or on behalf of NovaDel (or its Affiliates or its sublicensees), on the one hand, and Licensee (or its Affiliates or Sublicensees), on the other hand, in connection with the work conducted under or in connection with this Agreement, whether or not patented or patentable; and (b) Patents (the "Joint Patents") and other intellectual property rights with respect thereto (collectively, the "Joint Technology"). Each Party shall promptly disclose to the other Party in writing, and shall cause its Affiliates, licensees and sublicensees to so disclose, the development, making, conception or reduction to practice of any Joint Technology.
Ownership of Joint Technology. (a) All Joint Technology will be owned jointly by Gigabeam and Sophia, and each party will retain full ownership under any patents and any trade secret rights therein, with full ownership rights in any field and, subject to the licenses granted in Section 5.4 below, the right to sublicense without the consent of the other party, without obligation to account to the other party. The laws of the United States with respect to joint ownership of inventions will apply in all jurisdictions giving force and effect to this Agreement.
Ownership of Joint Technology. Subject to Section 5.1.2 and the license grants under Article 2, deCODE and at least one of Medarex and Genmab (the "JOINT INVENTORS") shall each own an equal, undivided interest in any and all (i) Information and Inventions, conceived, discovered, developed or otherwise made, as necessary to establish authorship, inventorship or ownership under Applicable Law, jointly by or on behalf of such Joint Inventors (or, with respect to each Joint Inventor, its Affiliates or, to the extent permitted, its sublicensees), in connection with the work conducted under or in connection with this Agreement, whether or not patented or patentable, but excluding any Mice Materials or Mice-Related Technology; and (ii) Patents (the "JOINT PATENTS") and other intellectual property rights with respect thereto (collectively, the "JOINT TECHNOLOGY"); provided, however, that neither a Joint Inventor nor any of its Affiliates, licensees or sublicensees shall, directly or indirectly, Exploit any Joint Technology or other such intellectual property rights without the consent of the other Joint Inventor(s), not to be unreasonably withheld or delayed, except that each Party shall have the right to Exploit such Joint Technology for internal research and discovery purposes (as opposed to the development, commercialization or other Exploitation of products or technology resulting therefrom) without the consent of the other Party; provided, however, that neither Party shall have the right to use Antibodies with respect to the Unilateral Targets except as set forth hereunder. Each Joint Inventor shall promptly disclose to the other Joint Inventor(s) in writing, and shall cause its Affiliates, licensees and sublicensees to so disclose, the development, making, conception or reduction to practice of any Joint Technology.
Ownership of Joint Technology. Subject to the license grants by one Party to the other under this Agreement, as between the Parties, all [***] conceived, created or discovered, by or on behalf of either Party or its Affiliates either alone or jointly with Third Party(ies), or by the Parties or their Affiliates jointly under or in connection with this Agreement, 100 whether or not conceived, created or discovered at a facility owned or controlled by such Party and whether or not patented or patentable (including any and all Patents and other intellectual property rights with respect thereto), will be owned in accordance with inventorship and in accordance with applicable Law in the United States. For the avoidance of doubt, subject to Section 11.6, and to the license grants in this Agreement, the Parties will each own an equal, undivided interest in any and all Joint Technology. Each Party will, and does hereby, assign, and will cause its Affiliates and subcontractors to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Joint Technology as well as any intellectual property rights with respect thereto, as is necessary to fully effect the joint ownership provided for in the foregoing sentence of this Section 11.4.
Ownership of Joint Technology. All discoveries, improvements and inventions conceived or first reduced to practice, as those terms are used before the U.S. Patent and Trademark Office, in the performance of this Agreement jointly by Solectron personnel and Brocade personnel (the "Joint Technology"), shall be the property [*] Each party shall execute all documents and take such further actions as may be reasonably required to evidence, perfect or enforce any such assignment. [*]
Ownership of Joint Technology. Subject to Section 7.2.1 (and excluding Pfizer Improvements and BioNTech Improvements), the Parties will jointly own any Joint Technology. Subject to (a) the grant of licenses or sublicenses to Pfizer under Section 2.1, (b) BioNTech’s representations, warranties and covenants under Section 9 and (c) the Parties’ other rights and obligations under this Agreement (including Section 2.10.1), each Party will be free to exploit, either itself or through the grant of licenses to Third Parties (which Third Party licenses may be further sublicensed), Joint Technology throughout the world without restriction, without the need to obtain further consent from or provide notice to the other Party, and without any duty to account or otherwise make any payment of any compensation to the other Party.
Ownership of Joint Technology. The Parties shall jointly own any Joint Technology. Subject to the grant of licenses to AMAG under Section 2 and the Parties’ other rights and obligations under this Agreement, each Party shall be free to exploit, either itself or through the grant of licenses to Third Parties (which Third Party licenses may be further sublicensed), Joint Patent Rights and Joint Know-How throughout the world without restriction, without the need to obtain further consent from or provide notice to the other Party, and without any duty to account or otherwise make any payment of any compensation to the other Party.
Ownership of Joint Technology. Subject to Sections 7.1.3 and 7.1.4 and the license grants under Article 3, the Parties shall each own [*] in any Joint Technology; provided, however, that, except as otherwise expressly provided in this Agreement, neither a Party nor any of its Affiliates, licensees or sublicensees shall, directly or indirectly, Exploit any Joint Technology, or any intellectual property rights with respect thereto, without the consent of the other Party, not to be unreasonably withheld or delayed, except that each Party shall have the right to Exploit such Joint Technology for research and discovery purposes (as opposed to the development, commercialization or other Exploitation of products or technology resulting therefrom), and to license others to do so, without the consent of the other Party. Each Party shall promptly disclose to the other Party in writing, and shall cause its Affiliates, licensees and sublicensees to so disclose, the development, making, conception or reduction to practice of any Joint Technology.
Ownership of Joint Technology. Subject to Section 11.2.1, 11.2.2 and 11.2.3, the Parties will jointly own any Joint Technology. Subject to (a) the grant of licenses or sublicenses under Section 3, (b) BioNTech’s representations, warranties and covenants under Section 13 and (c) the Parties’ other rights and obligations under this Agreement (including Section 3.11), each Party will be free to exploit, either itself or through the grant of licenses to Third Parties (which Third Party licenses may be further sublicensed), Joint Technology throughout the world without restriction, without the need to obtain further consent from or provide notice to the other Party, and without any duty to account or otherwise make any payment of any compensation to the other Party.
Ownership of Joint Technology. Subject to the ownership rights specified in Sections 12.1 and 12.2, [*] own all right, title and interest in the Joint Technology and all Intellectual Property Rights therein, and [*] use the Joint Technology and all Intellectual Property Rights therein without restriction and for any reason. [*] will execute such documents, render such assistance, and take such other action as [*] may reasonably request, at [*] expense, to apply for, register, perfect, confirm and protect [*] rights in the Joint Technology.
